Award
Food and Drug Administration 7R01FD007547-03
Phase I/II trial of sitagliptin, bortezomib and post-transplant cyclophosphamide for GvHD prophylaxis; IND 158327 (09/03/2021)
Recipient
FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
Award Amount
$648,608.00
Ceiling
$648,608.00
Awarded
September 26, 2025
Identifier
7R01FD007547-03
Award for a Phase I/II clinical trial on GvHD prophylaxis using sitagliptin, bortezomib, and post-transplant cyclophosphamide funded by the FDA.
Description
This project involves a Phase I/II clinical trial for GvHD prophylaxis using sitagliptin, bortezomib, and post-transplant cyclophosphamide, funded by the FDA, with an award amount of approximately $648,608, starting September 15, 2023, and ending August 31, 2026.